A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals With Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA)
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 15 Aug 2019 Planned initiation date changed from 31 May 2019 to 30 Sep 2019.
- 13 May 2019 According to a Celgene Corporation media release, AIDS Malignancy Consortium is the sponsor of this study.
- 26 Mar 2019 Planned End Date changed from 31 Jan 2021 to 31 May 2021.